← All trials
NCT03179475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2017
- Primary completion
- Jun 1, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of British ColumbiaLead sponsor
- Vancouver Coastal HealthCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of British ColumbiaReponsible party - principal investigator
- International Collaboration On Repair Discoveries (ICORD)Collaborator
- Purdue PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.